查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1887177

前列腺癌放射治療市場規模、佔有率、成長及全球產業分析：依類型、應用和地區劃分的洞察與預測（2024-2032 年）

Prostate Cancer Radiation Therapeutics Market Size, Share, Growth and Global Industry Analysis By Type & Application, Regional Insights and Forecast to 2024-2032
出版日期: | 出版商: Fortune Business Insights Pvt. Ltd. | 英文 189 Pages | 商品交期: 請詢問到貨日

價格

攝護腺癌放射治療市場成長驅動因素

受前列腺癌發病率上升、標靶放射性藥物療法的廣泛應用以及全球範圍內先進腫瘤治療服務可及性的提高等因素驅動，全球前列腺癌放射治療市場正進入快速增長期。根據最新的市場評估，2024年全球市場規模為19.6億美元，預計2025年將顯著增長至25.8億美元，並預計到2032年將達到151.9億美元，2025年至2032年的複合年增長率高達28.8%。憑藉其先進的醫療基礎設施和健全的報銷政策，北美在2024年以62.75%的市佔率引領全球市場。

市場概覽及主要成長驅動因素

攝護腺癌是男性最常見的癌症之一，其全球發生率的不斷上升推動了對有效治療方法的需求。 2022年，世界癌症研究基金會報告全球新增前列腺癌病例1,467,854例，凸顯了標靶治療的迫切性。放射療法，特別是使用鐳-223和镥-177等放射性同位素的放射療法，因其卓越的精準性而迅速普及。這些療法能將輻射直接輸送到癌細胞，同時最大限度地減少對健康組織的損傷，與傳統的體外放射療法相比具有顯著優勢。

镥-177尤其憑藉強勁的監管勢頭和突破性的產品上市，引領著市場。諾華公司的放射性配體療法Pulvict（Lu-177）為前列腺特異性抗原陽性轉移性去勢抵抗性前列腺癌（mCRPC）樹立了新的治療標準，大大推動了該領域的發展。

推動市場成長的因素

推動市場成長的關鍵因素之一是人口老化。前列腺癌的發生率隨著年齡的增長而顯著增加。根據美國臨床腫瘤學會2023年的報告，60%的前列腺癌病例發生在65歲及以上的男性中，這凸顯了影響治療需求的人口結構變化。

不斷擴大的宣傳活動和有利的報銷制度也在促進早期診斷和治療。拜耳公司和諾華公司等大型企業強大的創新研發管線正在推動下一代放射性藥物療法的廣泛應用。

市場限制因子

儘管成長前景可觀，但高昂的治療費用仍是重要的限制因素。放射性同位素的研發和特殊生產流程的需求顯著提高了價格。例如，一瓶Pluvicto的價格約為50,856美元，這給低收入地區的患者帶來了獲取困難。此外，新興市場監管的複雜性和核醫學基礎設施的匱乏阻礙了其更廣泛的應用。

機會與新興趨勢

製藥公司與放射性同位素生產商之間日益密切的合作正在創造新的機遇，以支持治療範圍的擴大。 2024年，Alyceum Therapeutics與Eckert & Ziegler合作，建立了Ac-225和Lu-177等同位素的全球供應鏈，從而增強了其創新產品線。

一個關鍵的新興趨勢是診療一體化（theranostics），它將診斷影像與標靶治療相結合。這種個人化治療模式提高了治療的精準度，並有助於提高存活率。例如，Clarity Pharmaceuticals的SECuRE試驗正在開髮用於治療轉移性去勢抵抗性前列腺癌的64Cu/67Cu-SAR-bisPSMA，這反映了產業向精準腫瘤學的轉變。

區域展望

預計北美地區在2024年將達到12.3億美元，由於其前列腺癌發病率高、擁有先進的核醫學設施以及大量的研發投入，北美地區仍將是關鍵區域。美國憑藉FDA的積極推動，包括Clarity Pharmaceuticals公司的67Cu-SAR-bisPSMA獲得2025年快速通道資格，保持領先地位。

歐洲則位居第二，這得益於Movember等提高公眾意識的活動以及標靶治療藥物的普及。

亞太地區是成長最快的地區（年複合成長率約33%），這主要受人口老化和攝護腺癌診斷病例增加的推動。光是澳洲在2024年就將通報26,400例新病例，佔男性所有癌症診斷病例的28%。

在阿拉伯聯合大公國（阿聯酋）和世界其他地區，精準醫療領域的投資正在加速成長，布爾齊爾癌症研究所將於2024年開業便是最好的例證。

目錄

第一章：引言

第二章：摘要整理

第三章：市場動態

  • 市場驅動因素
  • 市場限制因素
  • 市場機遇
  • 市場趨勢

第四章：主要發現

  • 2024年主要國家及地區攝護腺癌盛行率
  • 主要公司產品線分析
  • 替代療法概述
  • 新產品發布狀況主要公司
  • 關鍵產業趨勢（併購、合作等）
  • 新冠疫情對市場的影響

第五章：全球前列腺癌放射治療市場分析、洞察與預測（2019-2032）

  • 市場分析、洞察與預測 - 依放射性同位素劃分
    • 鐳-223
    • 镥-177
    • 其他
  • 市場分析、洞察與預測 - 依類型劃分
    • 轉移性去勢抵抗性攝護腺癌
    • 非轉移性去勢抵抗性攝護腺癌
  • 市場分析、洞察與預測 - 依最終用戶劃分
    • 醫院
    • 專科診所
    • 其他
  • 市場分析、洞察與預測 - 依地區劃分
    • 北美
    • 歐洲
    • 亞太地區
    • 世界其他地區

第六章：北美攝護腺癌放射治療市場分析、洞察與預測（2019-2032）

  • 依國家劃分
    • 美國
    • 加拿大

第七章：歐洲前列腺癌放射治療市場分析、洞察與預測（2019-2032）

  • 依國家劃分
    • 德國
    • 英國
    • 法國
    • 義大利
    • 西班牙
    • 斯堪的納維亞半島
    • 其他地區歐洲

第八章 亞太地區攝護腺癌放射治療市場分析、洞察與預測（2019-2032）

  • 依國家劃分
    • 中國
    • 日本
    • 印度
    • 澳大利亞
    • 東南亞
    • 亞太其他地區

第九章：世界其他地區前列腺癌放射治療市場分析、洞察與預測（2019-2032）

第十章：競爭分析

  • 全球市佔率分析（2024）
  • 公司簡介
  • 諾華公司
  • 拜耳公司
  • 泰利克斯製藥股份有限公司
  • 阿瑞斯姆公司治療學
  • Radiopharm Theranostics Limited
  • Lantheus Holdings, Inc.
  • Clarity Pharmaceuticals
Product Code: FBI112713

Growth Factors of prostate cancer radiation therapeutics Market

The global prostate cancer radiation therapeutics market is entering a high-growth phase driven by rising prostate cancer incidence, increasing adoption of targeted radiopharmaceutical therapies, and expanding access to advanced oncology care worldwide. According to the latest market assessment, the global market was valued at USD 1.96 billion in 2024, is projected to grow significantly to USD 2.58 billion in 2025, and is expected to reach USD 15.19 billion by 2032, reflecting an exceptional CAGR of 28.8% (2025-2032). North America led the global landscape with 62.75% market share in 2024, supported by advanced healthcare infrastructure and robust reimbursement policies.

Market Overview and Key Growth Factors

Prostate cancer remains one of the most commonly diagnosed cancers in men, and the rising global patient pool continues to drive demand for effective treatment options. In 2022, the World Cancer Research Fund recorded 1,467,854 new prostate cancer cases worldwide, highlighting the urgent need for targeted therapies. Radiation therapeutics, especially the use of radioisotopes such as Radium-223 and Lutetium-177, are gaining rapid traction due to their superior precision. These treatments deliver radiation directly to cancer cells while minimizing damage to healthy tissue-a major advantage over conventional external beam radiation therapies.

Lutetium-177, in particular, dominates the market due to strong regulatory momentum and landmark product launches. Novartis' radioligand therapy Pluvicto (Lu-177) has set a new standard of care for prostate-specific membrane antigen-positive metastatic castration-resistant prostate cancer (mCRPC), contributing significantly to the segment's expansion.

Drivers Strengthening Market Growth

A major driver fueling the growth trajectory is the rising geriatric population, as prostate cancer prevalence increases significantly with age. In 2023, the American Society of Clinical Oncology reported that 60% of prostate cancer cases occur in men over 65, highlighting the demographic shift influencing treatment demand.

Growing awareness programs and favorable reimbursement structures also promote early diagnosis and wider treatment adoption. Strong innovation pipelines, supported by major players like Bayer AG and Novartis AG, are advancing the availability of next-generation radiopharmaceutical therapies.

Market Restraints

Despite promising growth, high treatment costs remain a critical restraint. The development of radioisotopes and the specialized manufacturing required contribute to significantly high prices. For instance, the cost of a single vial of Pluvicto can reach approximately USD 50,856, posing accessibility challenges in low-income regions. Additionally, regulatory complexity and limited nuclear medicine infrastructure in emerging markets restrict broader adoption.

Opportunities and Emerging Trends

Growing collaborations among pharmaceutical companies and radioisotope manufacturers are creating new opportunities to support therapy expansion. In 2024, Ariceum Therapeutics partnered with Eckert & Ziegler for a global supply of isotopes such as Ac-225 and Lu-177, strengthening innovation pipelines.

A major emerging trend is the theranostics approach, which integrates diagnostic imaging with targeted therapy. This personalized treatment model enhances precision and improves survival outcomes. For example, Clarity Pharmaceuticals' SECuRE trial is advancing the development of 64Cu/67Cu-SAR-bisPSMA for metastatic castration-resistant prostate cancer, reflecting the industry's shift toward precision oncology.

Regional Outlook

North America, valued at USD 1.23 billion in 2024, remains the leading region due to a high prostate cancer burden, advanced nuclear medicine facilities, and significant R&D investment. The U.S. maintains dominance, supported by strong FDA activity, including the 2025 Fast Track Designation for Clarity Pharmaceuticals' 67Cu-SAR-bisPSMA.

Europe ranks second, driven by awareness movements like Movember and expanded access to targeted therapies.

Asia Pacific is the fastest-growing region (~33% CAGR), propelled by a rising elderly population and increasing prostate cancer diagnoses. Australia alone reported 26,400 new cases in 2024, accounting for 28% of total male cancer diagnoses.

Rest of the World markets such as the UAE are accelerating investments in precision medicine, evidenced by the 2024 launch of Burjeel Cancer Institute.

Competitive Landscape

The market is highly consolidated, with major players including Novartis AG, Bayer AG, Lantheus Holdings, Telix Pharmaceuticals, Ariceum Therapeutics, Radiopharm Theranostics, and Clarity Pharmaceuticals. Strategic collaborations, acquisitions, and regulatory approvals continue to shape the competitive environment, boosting innovation and treatment accessibility globally.

Segmentation By Radioisotope, Type, End-User, and Region

By Radioisotope * Radium-223

  • Lutetium-177
  • Others

By Type * Metastatic Castration-Resistant Prostate Cancer

  • Non-Metastatic Castration-Resistant Prostate Cancer

By End-User * Hospitals

  • Specialty Clinics
  • Others

By Region * North America (By Radioisotopes, Type, End-User, and Country)

U.S.

Canada

  • Europe (By Radioisotopes, Type, End-User, and Country/Sub-region)

Germany

U.K.

France

Spain

Italy

Rest of Europe

  • Asia Pacific (By Radioisotopes, Type, End-User, and Country/Sub-region)

China

Japan

India

Australia

Rest of Asia Pacific

  • Rest of the World (By Radioisotopes, Type, and End-User)

Table of Content

1. Introduction

  • 1.1. Research Scope
  • 1.2. Market Segmentation
  • 1.3. Research Methodology
  • 1.4. Definitions and Assumptions

2. Executive Summary

3. Market Dynamics

  • 3.1. Market Drivers
  • 3.2. Market Restraints
  • 3.3. Market Opportunities
  • 3.4. Market Trends

4. Key Insights

  • 4.1. Prevalence of Prostate Cancer - by Key Countries/Regions, 2024
  • 4.2. Pipeline Analysis, by Key Players
  • 4.3. Overview of Alternative Therapies
  • 4.4. New Product Launches, by Key Players
  • 4.5. Key Industry Developments (Mergers, Acquisitions, Partnerships, etc.)
  • 4.6. Impact of COVID-19 on the Market

5. Global Prostate Cancer Radiation Therapeutics Market Analysis, Insights and Forecast, 2019-2032

  • 5.1. Market Analysis, Insights and Forecast - By Radioisotope
    • 5.1.1. Radium-223
    • 5.1.2. Lutetium-177
    • 5.1.3. Others
  • 5.2. Market Analysis, Insights and Forecast - By Type
    • 5.2.1. Metastatic Castration-Resistant Prostate Cancer
    • 5.2.2. Non-Metastatic Castration-Resistant Prostate Cancer
  • 5.3. Market Analysis, Insights and Forecast - By End-user
    • 5.3.1. Hospitals
    • 5.3.2. Specialty Clinics
    • 5.3.3. Others
  • 5.4. Market Analysis, Insights and Forecast - Region
    • 5.4.1. North America
    • 5.4.2. Europe
    • 5.4.3. Asia Pacific
    • 5.4.4. Rest of the World

6. North America Prostate Cancer Radiation Therapeutics Market Analysis, Insights and Forecast, 2019-2032

  • 6.1. Market Analysis, Insights and Forecast - By Radioisotope
    • 6.1.1. Radium-223
    • 6.1.2. Lutetium-177
    • 6.1.3. Others
  • 6.2. Market Analysis, Insights and Forecast - By Type
    • 6.2.1. Metastatic Castration-Resistant Prostate Cancer
    • 6.2.2. Non-Metastatic Castration-Resistant Prostate Cancer
  • 6.3. Market Analysis, Insights and Forecast - By End-user
    • 6.3.1. Hospitals
    • 6.3.2. Specialty Clinics
    • 6.3.3. Others
  • 6.4. Market Analysis, Insights and Forecast - By Country
    • 6.4.1. U.S.
    • 6.4.2. Canada

7. Europe Prostate Cancer Radiation Therapeutics Market Analysis, Insights and Forecast, 2019-2032

  • 7.1. Market Analysis, Insights and Forecast - By Radioisotope
    • 7.1.1. Radium-223
    • 7.1.2. Lutetium-177
    • 7.1.3. Others
  • 7.2. Market Analysis, Insights and Forecast - By Type
    • 7.2.1. Metastatic Castration-Resistant Prostate Cancer
    • 7.2.2. Non-Metastatic Castration-Resistant Prostate Cancer
  • 7.3. Market Analysis, Insights and Forecast - By End-user
    • 7.3.1. Hospitals
    • 7.3.2. Specialty Clinics
    • 7.3.3. Others
  • 7.4. Market Analysis, Insights and Forecast - By Country/ Sub-Region
    • 7.4.1. Germany
    • 7.4.2. U.K.
    • 7.4.3. France
    • 7.4.4. Italy
    • 7.4.5. Spain
    • 7.4.6. Scandinavia
    • 7.4.7. Rest of Europe

8. Asia Pacific Prostate Cancer Radiation Therapeutics Market Analysis, Insights and Forecast, 2019-2032

  • 8.1. Market Analysis, Insights and Forecast - By Radioisotope
    • 8.1.1. Radium-223
    • 8.1.2. Lutetium-177
    • 8.1.3. Others
  • 8.2. Market Analysis, Insights and Forecast - By Type
    • 8.2.1. Metastatic Castration-Resistant Prostate Cancer
    • 8.2.2. Non-Metastatic Castration-Resistant Prostate Cancer
  • 8.3. Market Analysis, Insights and Forecast - By End-user
    • 8.3.1. Hospitals
    • 8.3.2. Specialty Clinics
    • 8.3.3. Others
  • 8.4. Market Analysis, Insights and Forecast - By Country/ Sub-Region
    • 8.4.1. China
    • 8.4.2. Japan
    • 8.4.3. India
    • 8.4.4. Australia
    • 8.4.5. Southeast Asia
    • 8.4.6. Rest of Asia Pacific

9. Rest of the World Prostate Cancer Radiation Therapeutics Market Analysis, Insights and Forecast, 2019-2032

  • 9.1. Market Analysis, Insights and Forecast - By Radioisotope
    • 9.1.1. Radium-223
    • 9.1.2. Lutetium-177
    • 9.1.3. Others
  • 9.2. Market Analysis, Insights and Forecast - By Type
    • 9.2.1. Metastatic Castration-Resistant Prostate Cancer
    • 9.2.2. Non-Metastatic Castration-Resistant Prostate Cancer
  • 9.3. Market Analysis, Insights and Forecast - By End-user
    • 9.3.1. Hospitals
    • 9.3.2. Specialty Clinics
    • 9.3.3. Others

10. Competitive Analysis

  • 10.1. Global Market Share Analysis (2024)
  • 10.2. Company Profiles (Overview, Products, SWOT analysis, Recent developments, strategies, financials (based on availability))
    • 10.2.1. Novartis AG
    • 10.2.2. Bayer AG
    • 10.2.3. Telix Pharmaceuticals Limited
    • 10.2.4. Ariceum Therapeutics
    • 10.2.5. Radiopharm Theranostics Limited
    • 10.2.6. Lantheus Holdings, Inc.
    • 10.2.7. Clarity Pharmaceuticals

List of Tables

  • Table 1: Global Prostate Cancer Radiation Therapeutics Market Revenue (USD billion) Forecast, by Radioisotope, 2019-2032
  • Table 2: Global Prostate Cancer Radiation Therapeutics Market Revenue (USD billion) Forecast, by Type, 2019-2032
  • Table 3: Global Prostate Cancer Radiation Therapeutics Market Revenue (USD billion) Forecast, by End-User, 2019-2032
  • Table 4: Global Prostate Cancer Radiation Therapeutics Market Revenue (USD billion) Forecast, by Region, 2019-2032
  • Table 5: North America Prostate Cancer Radiation Therapeutics Market Revenue (USD billion) Forecast, by Radioisotope, 2019-2032
  • Table 6: North America Prostate Cancer Radiation Therapeutics Market Revenue (USD billion) Forecast, by Type, 2019-2032
  • Table 7: North America Prostate Cancer Radiation Therapeutics Market Revenue (USD billion) Forecast, by End-User, 2019-2032
  • Table 8: North America Prostate Cancer Radiation Therapeutics Market Revenue (USD billion) Forecast, By Country, 2019-2032
  • Table 9: Europe Prostate Cancer Radiation Therapeutics Market Revenue (USD billion) Forecast, by Radioisotope, 2019-2032
  • Table 10: Europe Prostate Cancer Radiation Therapeutics Market Revenue (USD billion) Forecast, by Type, 2019-2032
  • Table 11: Europe Prostate Cancer Radiation Therapeutics Market Revenue (USD billion) Forecast, by End-User, 2019-2032
  • Table 12: Europe Prostate Cancer Radiation Therapeutics Market Revenue (USD billion) Forecast, By Country/ Sub-region, 2019-2032
  • Table 13: Asia Pacific Prostate Cancer Radiation Therapeutics Market Revenue (USD billion) Forecast, by Radioisotope, 2019-2032
  • Table 14: Asia Pacific Prostate Cancer Radiation Therapeutics Market Revenue (USD billion) Forecast, by Type, 2019-2032
  • Table 15: Asia Pacific Prostate Cancer Radiation Therapeutics Market Revenue (USD billion) Forecast, by End-User, 2019-2032
  • Table 16: Asia Pacific Prostate Cancer Radiation Therapeutics Market Revenue (USD billion) Forecast, By Country/ Sub-region, 2019-2032
  • Table 17: Rest of the World Prostate Cancer Radiation Therapeutics Market Revenue (USD billion) Forecast, by Radioisotope, 2019-2032
  • Table 18: Rest of the World Prostate Cancer Radiation Therapeutics Market Revenue (USD billion) Forecast, by Type, 2019-2032
  • Table 19: Rest of the World Prostate Cancer Radiation Therapeutics Market Revenue (USD billion) Forecast, by End-User, 2019-2032

List of Figures

  • Figure 1: Global Prostate Cancer Radiation Therapeutics Market Revenue Breakdown (USD billion, %) by Region, 2024 & 2032
  • Figure 2: Global Prostate Cancer Radiation Therapeutics Market Value Share (%), by Radioisotope, 2024 & 2032
  • Figure 3: Global Prostate Cancer Radiation Therapeutics Market Value Share (%), by Type, 2024 & 2032
  • Figure 4: Global Prostate Cancer Radiation Therapeutics Market Value Share (%), by End-User, 2024 & 2032
  • Figure 5: North America Prostate Cancer Radiation Therapeutics Market Value (USD billion), by Radioisotope, 2024 & 2032
  • Figure 6: North America Prostate Cancer Radiation Therapeutics Market Value Share (%), by Radioisotope, 2024
  • Figure 7: North America Prostate Cancer Radiation Therapeutics Market Value (USD billion), by Type, 2024 & 2032
  • Figure 8: North America Prostate Cancer Radiation Therapeutics Market Value Share (%), by Type, 2024
  • Figure 9: North America Prostate Cancer Radiation Therapeutics Market Value (USD billion), by End-User, 2024 & 2032
  • Figure 10: North America Prostate Cancer Radiation Therapeutics Market Value Share (%), by End-User, 2024
  • Figure 11: North America Prostate Cancer Radiation Therapeutics Market Value (USD billion), By Country, 2024 & 2032
  • Figure 12: North America Prostate Cancer Radiation Therapeutics Market Value Share (%), By Country, 2024
  • Figure 13: Europe Prostate Cancer Radiation Therapeutics Market Value (USD billion), by Radioisotope, 2024 & 2032
  • Figure 14: Europe Prostate Cancer Radiation Therapeutics Market Value Share (%), by Radioisotope, 2024
  • Figure 15: Europe Prostate Cancer Radiation Therapeutics Market Value (USD billion), by Type, 2024 & 2032
  • Figure 16: Europe Prostate Cancer Radiation Therapeutics Market Value Share (%), by Type, 2024
  • Figure 17: Europe Prostate Cancer Radiation Therapeutics Market Value (USD billion), by End-User, 2024 & 2032
  • Figure 18: Europe Prostate Cancer Radiation Therapeutics Market Value Share (%), by End-User, 2024
  • Figure 19: Europe Prostate Cancer Radiation Therapeutics Market Value (USD billion), By Country/ Sub-region, 2024 & 2032
  • Figure 20: Europe Prostate Cancer Radiation Therapeutics Market Value Share (%), By Country/ Sub-region, 2024
  • Figure 21: Asia Pacific Prostate Cancer Radiation Therapeutics Market Value (USD billion), by Radioisotope, 2024 & 2032
  • Figure 22: Asia Pacific Prostate Cancer Radiation Therapeutics Market Value Share (%), by Radioisotope, 2024
  • Figure 23: Asia Pacific Prostate Cancer Radiation Therapeutics Market Value (USD billion), by Type, 2024 & 2032
  • Figure 24: Asia Pacific Prostate Cancer Radiation Therapeutics Market Value Share (%), by Type, 2024
  • Figure 25: Asia Pacific Prostate Cancer Radiation Therapeutics Market Value (USD billion), by End-User, 2024 & 2032
  • Figure 26: Asia Pacific Prostate Cancer Radiation Therapeutics Market Value Share (%), by End-User, 2024
  • Figure 27: Asia Pacific Prostate Cancer Radiation Therapeutics Market Value (USD billion), By Country/ Sub-region, 2024 & 2032
  • Figure 28: Asia Pacific Prostate Cancer Radiation Therapeutics Market Value Share (%), By Country/ Sub-region, 2024
  • Figure 29: Rest of the World Prostate Cancer Radiation Therapeutics Market Value (USD billion), by Radioisotope, 2024 & 2032
  • Figure 30: Rest of the World Prostate Cancer Radiation Therapeutics Market Value Share (%), by Radioisotope, 2024
  • Figure 31: Rest of the World Prostate Cancer Radiation Therapeutics Market Value (USD billion), by Type, 2024 & 2032
  • Figure 32: Rest of the World Prostate Cancer Radiation Therapeutics Market Value Share (%), by Type, 2024
  • Figure 33: Rest of the World Prostate Cancer Radiation Therapeutics Market Value (USD billion), by End-User, 2024 & 2032
  • Figure 34: Rest of the World Prostate Cancer Radiation Therapeutics Market Value Share (%), by End-User, 2024
  • Figure 35: Global Prostate Cancer Radiation Therapeutics Market Share (%), By Company, 2024